Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Neomorph Secures $109M

SAN DIEGO, CA, Neomorph announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs.
Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD.

Neomorph is building a leading protein degradation entity, focused on "molecular glue" degraders. Neomorph's mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against "undruggable targets."

Neomorph comprises scientific leaders from academia and industry who have demonstrated years of commitment and success in the field, and who remain dedicated to advancing the science and technology and delivering highly impactful drugs. The Neomorph team intends to concentrate their efforts on accelerating molecular glue drug discovery, while shepherding a pipeline of projects through clinical development. The Company maintains an important close affiliation with the Center for Protein Degradation at the Dana Farber Cancer Institute.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors